Navigation Links
Progenika Receives CE Mark for First DNA Chip to Detect Mutations in Lipoprotein Lipase (LPL) Gene
Date:9/27/2010

Progenika Receives CE Mark for First DNA Chip to Detect Mutations in... -- BILBAO, Spain, September 27, 2010 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Medical Pharmaceuticals, Pharmaceuticals, Licensing, New Products & Services Click to view news release full screen  

Progenika Receives CE Mark for First DNA Chip to Detect Mutations in Lipoprotein Lipase (LPL) Gene

 

BILBAO, Spain, September 27, 2010 /PRNewswire-FirstCall/ --

- LPLchip(R) Rapidly and Precisely Detects Mutations Causing LPL Deficiency, a Cause of Acute Pancreatitis

- LPLchip(R) Identifies Patients who Could Benefit From Gene Therapy, Such as AMT's Glybera(R), Currently Under Review for EU Approval

Progenika Biopharma S.A., a pioneer in the field of personalized medicine, announced today that it has obtained the CE Mark allowing the sale in Europe of its LPLchip(R), the first DNA chip to detect mutations in the lipoprotein lipase (LPL) gene. This diagnostic tool rapidly diagnoses patients with complete and partial lipoprotein lipase deficiency (LPLD). The test has been developed under an agreement with Amsterdam Molecular Therapeutics Holding N.V. (Euronext: AMT), which has a gene therapy for patients with LPLD.

LPLD is characterised by a marked increase in triglycerides which can lead to serious complications such as acute recurring pancreatitis. Given the progressive nature of LPLD, early diagnosis is crucial to patients in order to reduce mortality and morbidity. The LPLchip(R) can precisely, quickly and economically detect more than 120 mutations in the LPL gene. The test uses Progenika's pioneering advanced DNAchip technology, which offers reliable and fast diagnosis. All that is required for analysis using the LPLchip(R) is a blood or saliva sample.

At present, there is no approved treatment for LPLD, only lifestyle moderation guidelines to minimize diets rich in fat. However, AMT has developed a new genetic treatment for LPLD, Glybera(R), which has been filed for marketing authorization with the European Medicines Agency (EMA) in early 2010. A decision on the approval is expected mid-2011.

Long term follow-up of two clinical studies conducted in Europe and Canada is ongoing, as is a third clinical study in Canada. In these three studies, Glybera(R) has shown a sizeable decrease in the incidence of pancreatitis, or acute inflammation of the pancreas, the most debilitating complication of LPLD. In addition, these studies indicate that Glybera(R) has an excellent safety profile.

About Progenika

The Progenika Group develops biochips in the field of personalised medicine aimed at the diagnosis, prognosis and prediction of response to treatment of complex illnesses in humans. The company offers molecular diagnostic tools in areas such as oncology, lipids, and nervous system disorders as well as the optimisation of their treatment.

Paramount among its technological developments are the LIPOchip(R) for the diagnosis of Familial Hypercholesterolaemia, and the BLOODchip(R) for ensuring compatibility in blood transfusions.

Founded in the year 2000, its research, development and production centres are located in the Biscay Technological Park and in Cambridge (Massachusetts, USA). It also has laboratories in the United Arab Emirates and in Kuwait. It has also set up commercial and intellectual property offices in Madrid and London.

At present, more than 150 scientists work in the company facilities and the company's products are sold in America, Europe and the Middle East.

http://www.progenika.com


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AMT Starts Development LPLChip(TM) With Progenika
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. CryoCor Receives FDA Approval for Right Atrial Flutter
8. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
9. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
10. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
11. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... "Company") (NASDAQ: UNIS ; ASX: UNS), a developer and ... for the second quarter of fiscal 2016 (three months ended December ... Financial Results for the Second Quarter of Fiscal 2016 ... the second quarter of fiscal 2016 was $4.5 million, compared to ... customers for the second quarter of fiscal 2016 were $17.8 million, ...
(Date:2/9/2016)... 2016  Axovant Sciences Ltd. (NYSE:  AXON), a ... of dementia, today announced further details of three ... functional aspects of Lewy body dementia, a disease ... Two out of the three studies were recently ... later this quarter. In addition, the Company reported ...
(Date:2/9/2016)... Hearing protection devices refer to the barriers that reduce ... ear. Hearing protection devices include earplugs, uniform attenuation earplug, ... users exposed to noise levels of over 80 dB ... inserted in the ear canal to protect the ear. ... sound perception with the help of acoustic filters. Earmuffs ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... ... production of its newest mobility device, the StandUp Walker. Made entirely in the ... in the last 50 years. , StandUp Walker’s novel patent-pending design offers 2-in-1 ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... LLC to help enterprises move workloads to the cloud. Cirracore provides a ... their cloud without traversing the Internet. Transformation Solutions (TSL Partners) provides a ...
(Date:2/9/2016)... ... February 09, 2016 , ... BioPlus Specialty Pharmacy (BioPlus), one ... ‘Pay It Forward’ program into 2016. BioPlus partners with several non-profit patient foundations ... , “Since our Pay It Forward program began, we are proud to have ...
(Date:2/9/2016)... ... ... On January 12, 2016 Paul McElwee, a CroppMetcalfe HVAC technician, visited a home ... any heat. Shortly after entering the home, Paul was able to identify the problem ... carbon monoxide into the home, at 2,000 parts per million in the flue. Anything ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton Stores, Inc. ... department stores, announced it has raised $176,000 to benefit the Breast Cancer Research ... Center at the University of Iowa, The Lynn Sage Cancer Research Foundation, and ...
Breaking Medicine News(10 mins):